Rare Disease Report
Patients & Caregivers


Head and neck cancers begin in the mouth, nose, throat, larynx, sinuses, or salivary glands. Most are squamous cell carcinomas.
H3B-8800, was granted orphan drug designation by the FDA for the treatment of patients with acute myeloid leukemia, and chronic myelomonocytic leukemia.
Mariann's plexiform fibrohistiocytic sarcoma had taken over most of her back. Her treatment required a donor that was compatible.
Nasopharyngeal cancer has been linked to the Epstein-Barr virus.
The FDA granted orphan drug designation to tesevatinib for treatment of non-small cell lung cancer with epithelial growth factor receptor-activating mutations.
The FDA accepted a supplemental New Drug Application and granted Priority Review for Zelboraf, a therapy for Erdheim-Chester disease with a BRAF V600 mutation.
TheFDA has approved Imbruvica (ibrutinib) for treating adults with chronic graft versus host disease (cGVHD) after failure of one or more treatments.
The FDA approved Idhifa (enasidenib) for treating patients with relapsed or refractory AML who have mutations in their IDH2 gene.
This Saturday, proceeds from shopping on QVC will go towards Ovarian Cancer Research Fund Alliance (OCRFA).
Proceeds from the sales will go to St. Jude Children's Research Hospital and the Epidermolysis Bullosa Medical Research Foundation.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.